Gynecologic Oncology Reports最新文献

{"title":"Embryonal rhabdomyosarcoma of the uterine corpus in a postmenopausal Woman: A case report and literature Review","authors":"Misako Omuro ,&nbsp;Yuichi Imai ,&nbsp;Yuki Ogawara ,&nbsp;Taichi Mizushima ,&nbsp;Erika Muraoka ,&nbsp;Shoji Yamanaka ,&nbsp;Satoshi Fujii ,&nbsp;Etsuko Miyagi","doi":"10.1016/j.gore.2025.101937","DOIUrl":"10.1016/j.gore.2025.101937","url":null,"abstract":"<div><h3>Background</h3><div>Rhabdomyosarcoma (RMS) is a rare malignant mesenchymal tumor, primarily affecting children. Occurrence in the uterine corpus of adults, particularly postmenopausal women, is extremely uncommon.</div></div><div><h3>Case Presentation</h3><div>A 60-year-old postmenopausal nulligravid woman presented with abnormal genital bleeding for three months. Pelvic examination revealed a friable mass extending from the uterine corpus. Biopsy confirmed embryonal RMS. She underwent modified radical hysterectomy with bilateral salpingo-oophorectomy for complete surgical resection. One cycle of adjuvant VAC chemotherapy (vincristine, actinomycin D, and cyclophosphamide) was administered but discontinued at her request. No residual disease was observed postoperatively, and she remains disease-free 12 months after surgery.</div></div><div><h3>Conclusion</h3><div>Adult-onset uterine corpus embryonal RMS is rare, and standardized treatment protocols are lacking. Early diagnosis, complete surgical resection, and individualized therapy are essential. A literature review highlights clinical characteristics, treatment strategies, and prognostic considerations.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"61 ","pages":"Article 101937"},"PeriodicalIF":1.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145044961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of racial differences in HER2 status and molecular subtype in grade 3 endometroid endometrial carcinoma","authors":"Sarah A. Ackroyd ,&nbsp;Gabrielle Sudilovsky ,&nbsp;Yan Che ,&nbsp;Jennifer A. Bennett ,&nbsp;S Diane Yamada ,&nbsp;Gini F Fleming","doi":"10.1016/j.gore.2025.101936","DOIUrl":"10.1016/j.gore.2025.101936","url":null,"abstract":"<div><h3>Objectives</h3><div>To characterize stage I-III Grade 3 endometroid endometrial cancer (Gr3 EEC) by molecular subtype and human epithelial growth factor receptor 2 (HER2) status and explore differences in characteristics by race.</div></div><div><h3>Methods</h3><div>We identified patients with a diagnosis of stage I-III Gr3 EEC from a single-institution health system cancer registry and pathologically confirmed the diagnosis. Review of the electronic health record was performed as needed to confirm patient characteristics. Next-generation sequencing (NGS) and immunohistochemical staining (IHC) for HER2 was performed on all primary tumors.</div></div><div><h3>Results</h3><div>Thirty-four primary cases remained classified as stage I-III Gr3 EEC after pathologic review and exclusion of cases lacking in-house primary tumor for re-review. Fifteen were categorized as microsatellite unstable (MSI; 44 %), 10 as copy number high (CNH; 29 %), six as polymerase E mutant (<em>POLE</em>mut; 17.6 %) and three as copy number low (CNL; 8.8 %). Thirteen patients were Black, 18 were White, and 3 had a race of “other and/or unknown”. HER2 status by IHC in the primary tumor was 0 (n = 7; 20.5 %), 1+ (n = 11; 32 %), 2+ (n = 14; 41 %), 3+ (n = 1; 3 %). There was no difference in the distribution of TCGA subtype or HER2 status by race.</div></div><div><h3>Conclusion</h3><div>In stage I-III stage Gr3 EEC HER2 positivity (3 + ) was uncommon, but expression at the 2 + level was frequent, and did not differ by race. In this limited sample, there were no differences in distribution of TCGA subtype amongst patients with grade 3 EEC. Other causes should be explored to explain reported differences in outcomes in EEC by race.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"61 ","pages":"Article 101936"},"PeriodicalIF":1.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144925326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary Ewing’s sarcoma of the vagina: A rare case report and literature review","authors":"Die Fan ,&nbsp;Xiaoxia Jiang ,&nbsp;Lin Wu ,&nbsp;Yujie Hao ,&nbsp;Chengbin Lu ,&nbsp;Zheng Li","doi":"10.1016/j.gore.2025.101949","DOIUrl":"10.1016/j.gore.2025.101949","url":null,"abstract":"<div><h3>Background</h3><div>Ewing’s sarcoma (ES) is an aggressive malignancy affecting bone and soft tissues, predominantly occurring in the skeletal system. The occurrence of Ewing’s sarcoma (ES) or primitive neuroectodermal tumor (PNET) with in the female genital tract is rare. Even rarer is its occurrence in the vagina, with only 22 cases reported to date. Accurate diagnosis necessitates a multifaceted approach that includes morphology, immunohistochemistry, and molecular pathology; the gold standard for diagnosis is next-generation sequencing (NGS), which is characterized by chromosomal translocations resulting in FET-ETS gene fusions.</div><div>Case description.</div><div>We present an exceptionally rare case of Ewing’s sarcoma in a 35-year-old woman of childbearing age. She exhibited a painless vaginal mass measuring approximately 2.5 × 2 × 0.9 cm, and according to the existing literature, our case represents the smallest tumor documented in primary vaginal Ewing’s sarcoma. Immunohistochemistry (IHC) revealed membrane positivity for CD99, along with positive expression of NKX2.2, FLI-1, and VIM. Furthermore, next-generation sequencing (NGS) conducted at the Affiliated Cancer Hospital of Fudan University identified an EWSR1-FLI1 gene fusion, thereby confirming the diagnosis of vaginal Ewing’s sarcoma.</div></div><div><h3>Conclusion</h3><div>Vaginal Ewing’s sarcoma is characterized by the absence of specific clinical manifestations and signs, along with a high rate of recurrence and metastasis. The management of these tumors primarily involves optimal local surgical intervention, followed by adjuvant therapies such as radiotherapy and/or chemotherapy.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"61 ","pages":"Article 101949"},"PeriodicalIF":1.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145105394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Malignant Brenner tumor with extensive clear cell features: A valuable diagnostic lesson learned from molecular tumor profiling and AI-based tumor differential tool","authors":"John A Steinharter ,&nbsp;Corinne Jansen ,&nbsp;Hassan Ghani ,&nbsp;Apsra Nasir ,&nbsp;Marzia Capelletti ,&nbsp;Ashley Stuckey ,&nbsp;M.Ruhul Quddus ,&nbsp;Yun-An Tseng","doi":"10.1016/j.gore.2025.101939","DOIUrl":"10.1016/j.gore.2025.101939","url":null,"abstract":"<div><h3>Background</h3><div>Malignant Brenner tumor (MBT) with extensive clear cell features mimicking an ovarian clear cell carcinoma (CCC) is exceedingly rare. This case report discusses the diagnostic challenges associated with this unusual histologic finding and highlights the value of molecular tumor profiling and artificial intelligence (AI)-based tools in tumor diagnostics.</div></div><div><h3>Case Summary</h3><div>A 55-year-old woman presented with a 17.7 cm complex left ovarian mass, which was initially diagnosed as ovarian clear cell carcinoma on the frozen and permanent H&amp;E sections. The subsequent next-generation sequencing (NGS) and an AI-based tumor differential tool predicted an 88 % match of urothelial origin for the ovarian tumor driven by strong expression of GATA3, uroplakin 2, and AMACR, while assigning 0 % match to ovarian CCC. The molecular and histologic discordance prompted pathologic re-evaluation. On the additional sections submitted from the ovarian tumor, a small component of benign Brenner tumor was identified adjacent to the tumor with extensive clear cell features. In addition, both the tumor cells exhibiting clear cell features and the benign Brenner tumor showed positive expression of urothelial markers by immunohistochemistry. The diagnosis was amended to MBT with extensive clear cell features. The NGS data was reviewed and showed the ovarian tumor harbored CDKN2A/B loss and a molecular triple phenotype (MDM2 amplification/TP53 wild-type/TERT wild-type), supporting the diagnosis of MBT and disfavoring metastatic urothelial carcinoma.</div></div><div><h3>Conclusion</h3><div>MBT should be considered in the differential diagnosis of ovarian neoplasms with clear cell features. Extensive tumor sampling combined with careful evaluation of the histologic and immunohistochemical features and molecular analysis is the key to accurate diagnosis. AI-based tumor differential tools are valuable adjuncts to tumor diagnostics when investigated with other pathological and clinical findings.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"61 ","pages":"Article 101939"},"PeriodicalIF":1.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144996724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of intraoperative ultrasound in resection of early-stage borderline ovarian tumors: A case series","authors":"Karthiga Natarajan ,&nbsp;Marilyn Boo ,&nbsp;Samir A. Saidi","doi":"10.1016/j.gore.2025.101817","DOIUrl":"10.1016/j.gore.2025.101817","url":null,"abstract":"<div><div>Borderline ovarian tumors (BOTs) commonly occur in women of reproductive age. For patients desiring fertility preservation, cystectomies are recommended as healthy ovarian tissue is spared. However, intraoperative identification of small BOTs can be challenging. Intraoperative ultrasound is a novel technique that enhances the visualization of anatomical structures, potentially allowing for a more precise excision of the ovarian lesion, which maximizes the preservation of healthy ovarian tissue. Although it has clear advantages, the literature on the use of intraoperative ultrasound in gynecological surgeries remains limited.</div><div>Cases: We describe a case series of four women aged between 20 and 33 years old who underwent ultrasound-guided laparoscopic cystectomy for early-stage BOTs.</div><div>Discussion: We demonstrate that intraoperative ultrasound in laparoscopic resection of early-stage BOTs improves visualization of the ovarian tissue, thereby minimizing the amount of healthy ovarian tissue excised, which optimizes fertility preservation in patients.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"61 ","pages":"Article 101817"},"PeriodicalIF":1.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144827767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Themes, perspectives, and educational quality of content related to #PapSmears on TikTok","authors":"Stephany Amezcua ,&nbsp;Matthew W. Lee ,&nbsp;Laurel S. Aberle ,&nbsp;Katelyn B. Furey ,&nbsp;Xiaoyue Mona Guo","doi":"10.1016/j.gore.2025.101964","DOIUrl":"10.1016/j.gore.2025.101964","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate TikTok videos with the hashtag #PapSmear and analyze their educational quality, themes, tone, creator, and engagement metrics.</div></div><div><h3>Methods</h3><div>A cross-sectional analysis of the top 150 TikTok videos with #PapSmear was conducted in September 2023. Videos were evaluated by four independent reviewers for engagement metrics, video topic, intent, tone, creator, and themes. The educational quality of videos was assessed using the brief DISCERN tool. Statistical analyses were performed to examine differences and relationships across groups.</div></div><div><h3>Results</h3><div>Among the 150 videos reviewed, 75.3 % focused on Pap smears, while 24.7 % discussed pelvic exams. Patients created 60.7 % of videos while healthcare providers contributed 39.3 %. Videos created by healthcare providers were more likely to be neutral or positive in tone and focus on educational content. Videos created by patients tended to have a negative tone, often focusing on personal experiences or comedy. Negative tones were significantly associated with higher engagement by “likes” and “shares” compared to neutral and positive tones. DISCERN scores were low across all videos. Healthcare provider videos did not score significantly higher than patient-generated content (p &gt; 0.05). 10 % (n = 15) of videos addressed trauma related to a Pap smear or pelvic exam.</div></div><div><h3>Conclusion</h3><div>Our analysis of the top 150 TikTok videos with #papsmear shows low educational quality across all creators, highlighting the difficulty of providing accurate health information on social media. To improve the quality and impact of health communication on social media, healthcare professionals might consider integrating relatable storytelling and appropriate humor while still prioritizing medical accuracy and trauma-informed messaging.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"61 ","pages":"Article 101964"},"PeriodicalIF":1.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145216526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment preferences of patients with recurrent or metastatic cervical cancer: a discrete choice experiment in the US","authors":"Premal H. Thaker ,&nbsp;Hui Lu ,&nbsp;Yitong J. Zhang ,&nbsp;Myrto Trapali ,&nbsp;Paul Swinburn ,&nbsp;Nicolas Krucien ,&nbsp;Doris White ,&nbsp;Joslyn Chaiprasert-Paguio ,&nbsp;Bhavana Pothuri ,&nbsp;Jie Ting","doi":"10.1016/j.gore.2025.101947","DOIUrl":"10.1016/j.gore.2025.101947","url":null,"abstract":"<div><h3>Objective</h3><div>This study assessed treatment preferences of patients with recurrent/metastatic cervical cancer, a disease with poor prognosis.</div></div><div><h3>Methods</h3><div>A survey with two discrete choice experiments was completed by 150 patients with recurrent/metastatic cervical cancer in the US. Discrete choice experiment 1 included treatment attributes, and discrete choice experiment 2 included risk mitigation plan attributes.</div></div><div><h3>Results</h3><div>Participants valued 12-month overall survival rate as the most important attribute, followed by disease control rate; both efficacy attributes were rated as more important than the risk of side effects such as peripheral neuropathy and corneal side effects. Participants’ willingness to accept a treatment profile requiring a risk mitigation plan was influenced by the number of clinic visits and out-of-pocket costs.</div></div><div><h3>Conclusions</h3><div>Patients with recurrent/metastatic cervical cancer prioritize overall survival and disease control rate as the most important attributes. These findings can be used to inform shared decision-making and treatment discussions among patients, clinicians, and the care team.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"61 ","pages":"Article 101947"},"PeriodicalIF":1.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145105399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Scholarly productivity during gynecologic oncology fellowship: A cross-sectional survey of graduates from 2020 to 2024","authors":"Glenn P. Boyles ,&nbsp;Chelsey I. Vranes ,&nbsp;Leslie H. Clark ,&nbsp;Kimberly Dessources ,&nbsp;J. Michael Straughn Jr","doi":"10.1016/j.gore.2025.101958","DOIUrl":"10.1016/j.gore.2025.101958","url":null,"abstract":"<div><h3>Objectives</h3><div>To characterize the scholarly accomplishments and attitudes regarding scholarly productivity among recent gynecologic oncology (GYO) fellowship graduates and identify factors which may influence academic productivity.</div></div><div><h3>Methods</h3><div>A 21-item web-based survey was distributed to individuals who had graduated from GYO fellowship within the past five years (2020–2024). Data on demographics, fellowship program characteristics, and scholarly accomplishments were collected. Descriptive statistics and univariate logistic regression were performed.</div></div><div><h3>Results</h3><div>115 individuals participated in the survey yielding a response rate of 31.2 %. The median number (min, max) of first-author published manuscripts was 4 (0, 18), conference posters was 4 (0, 30), and oral plenaries was 1 (0, 10). Graduates from programs with larger GYO clinical divisions were more likely to publish 4 or more first-author manuscripts compared to those from smaller divisions (OR 2.50; 95 % CI 1.09–5.74). The factors most frequently cited as supporting scholarly productivity were positive mentorship (65.4 %), access to existing databases (33.7 %), and timing of research year(s) (32.7 %). Reported barriers included clinical volume (63.5 %), inadequate technical support (36.5 %), and lack of mentorship (29.8 %). Fellows who had a clinical year prior to their dedicated research time were more likely to view timing of their research year(s) as contributory to their scholarly productivity (OR 2.89; 95 % CI 1.19–7.02).</div></div><div><h3>Conclusions</h3><div>This study provides valuable descriptive data on the scholarly accomplishments of recent GYO fellows. Clinical division size and timing of research year(s) seem to positively impact scholarly productivity.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"61 ","pages":"Article 101958"},"PeriodicalIF":1.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145105398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cervical HPV 18 detection is associated with high-grade cervical dysplasia in Kenyan and Ugandan women living with HIV","authors":"Miriam Nakalembe ,&nbsp;Collins Mpamani ,&nbsp;Jane Namugga ,&nbsp;Carolyn Nakisige ,&nbsp;Grace Banturaki ,&nbsp;Phillip Tonui ,&nbsp;Peter Itsura ,&nbsp;Omenge Orang’o ,&nbsp;Kapten Muthoka ,&nbsp;Anthony Ngeresa ,&nbsp;Beverly Musick ,&nbsp;Aaron Ermel ,&nbsp;Patrick Loehrer ,&nbsp;Darron R. Brown ,&nbsp;Yan Tong","doi":"10.1016/j.gore.2025.101953","DOIUrl":"10.1016/j.gore.2025.101953","url":null,"abstract":"<div><h3>Objectives</h3><div>Cervical cancer, caused by “high-risk” (HR) HPV, is the most common malignancy and the leading cause of cancer deaths among women living in Kenya and Uganda. Women living with HIV (WLWH) are at a high risk for HR-HPV infection. This longitudinal, observational cohort analysis was conducted to identify factors that are important among WLWH in prediction of cervical intraepithelial neoplasia grades 2 or 3 (CIN2/3).</div></div><div><h3>Methods</h3><div>Data of this analysis was based on a study of HPV natural history and cervical cancer among Kenyan and Ugandan WLWH. Demographic, behavioral and biological data were collected; HR-HPV DNA testing of cervical swabs was performed (Roche Cobas Assay); all WLWH underwent cervical biopsy on two occasions.</div></div><div><h3>Results</h3><div>Of 114 WLWH enrolled, the median age was 38.2 years. All WLWH were receiving ART during the study. CIN2/3 was found in 13 (11.4 %) WLWH; HPV 16 was detected in 10 (8.8 %); HPV 18 in 11 (9.6 %), and Non-16/18 HR-HPV in 62 (54.4 %). Aflatoxin exposure was not associated with CIN2/3 in this analysis. A multivariable logistic regression found that cervical detection of HPV 18 was significantly associated with CIN2/3 (OR = 6.36, 95 % CI = 1.36–29.75, p = 0.019), after adjusting for the effects of HIV viral load, CD4 counts, and Non-16/18 HR-HPV detection.</div></div><div><h3>Conclusions</h3><div>CIN2/3 was detected in 11.4% of WLWH; HPV 18 detection in cervical swabs was strongly associated with CIN2/3. Larger studies among WLWH are needed to determine optimal approaches for screening and treatment to prevent cervical cancer.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"61 ","pages":"Article 101953"},"PeriodicalIF":1.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145118557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnosis and treatment of a mixed ovarian malignant germ cell tumor with glioblastoma transformation","authors":"M.A. Sylvester ,&nbsp;D. Spinosa ,&nbsp;A. Encarnacion ,&nbsp;A. Berning ,&nbsp;J. Alldredge","doi":"10.1016/j.gore.2025.101945","DOIUrl":"10.1016/j.gore.2025.101945","url":null,"abstract":"<div><h3>Objectives</h3><div>Mixed malignant germ cell tumors of the ovary consist of two or more germ cell components, and are a rare but aggressive gynecologic malignancy which typically affect women in early reproductive years. Very few cases of mixed malignant germ cell tumors with glioblastoma component are reported in the literature, and little is known about the most appropriate chemotherapy regimen and long-term outcomes for these rare tumor presentations.</div></div><div><h3>Methods</h3><div>Presented here is the case of a 44-year-old female patient diagnosed with a stage III mixed malignant germ cell tumor of the ovary consisting of immature teratoma (95%) and yolk sac tumor (5%), with concurrent transformation of mature neural tissue to glioblastoma. The patient underwent primary staging surgery with evidence of gliomatosis peritonei on final pathology.</div></div><div><h3>Results</h3><div>In collaboration with neuro-oncology, the decision was made to not alter adjuvant treatment plan on account of the glioblastoma component of this case, so the patient underwent adjuvant chemotherapy with four cycles of bleomycin, etoposide, and cisplatin (BEP) and has been followed for 2.5 years from completion with no evidence of recurrence.</div></div><div><h3>Conclusions</h3><div>The case presented here discusses the rare presentation of mixed malignant germ cell tumor of the ovary with concurrent glioblastoma transformation and gliomatosis peritonei. While long-term outcomes cannot be concluded based on this case, excellent treatment response has been seen at 2.5 years, suggesting that traditional BEP therapy regiment should be considered for similar cases.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"61 ","pages":"Article 101945"},"PeriodicalIF":1.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145019716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}